FindTrial
Sign In

A Multicenter Retrospective Study Comparing the Efficacy of Neoadjuvant Chemoradiotherapy Combined with Immunotherapy versus Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

A Multicenter Retrospective Study Comparing the Efficacy of Neoadjuvant Chemoradiotherapy Combined with Immunotherapy versus Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116739
Enrollment
Unknown
Registered
2026-01-14
Start date
2026-01-20
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Observation group:N/A

Sponsors

Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age between 18 and 80 years; 2.Clinical diagnosis of thoracic esophageal squamous cell carcinoma (ESCC), staged as T1N1-3M0 or T2-4aN0-3M0; 3.Completion of neoadjuvant therapy followed by transthoracic esophagectomy; 4.Complete clinical data with comprehensive treatment information available.

Exclusion criteria

Exclusion criteria: 1.History of prior malignant tumors; 2.Failure to complete neoadjuvant therapy or undergoing salvage surgery; 3.Inability to evaluate treatment response due to missing examination data; 4.Missing clinical data or follow-up information.

Design outcomes

Primary

MeasureTime frame
2 year event-free survival (EFS); 2 year overall survival (OS);—

Secondary

MeasureTime frame
Pathological Complete Response (pCR);Major Pathological Response(MPR);—

Countries

China

Contacts

Public ContactJianhua Fu

Sun Yat-sen University Cancer Center

aoyong@sysucc.org.cn+86 20 8734 3450

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026